Abstracts

Citation

Michael Boivin, Alla Sikorskii, Jim Aizire, Limbika Maliwichi-Senganimalunje, Lillian Wambuzi Ogwang, Newton Kumwenda, Itziar Familiar, Horacio Escudero-Ruisenoir, Taha Taha, Mary Glenn Fowler. Neurodevelopment of Ugandan and Malawian PROMISE and Control children at age 12 and 24 months. Presented at: CROI 2016.

Citation

P Rawat, SA Spector. Development and Characterization of a Human Microglia Cell Model of HIV-1 Infection. Presented at: CROI 2016.

Citation

Andrew Wiznia, Carmelita Alvero, Terry Fenton, Kathleen George, Ellen Townley, Rohan Hazra, Barb Heckman, Annie Buchannan, Cindy Vavro, Rolando Viani on behalf of the P1093 study team. IMPAACT 1093: Dolutegravir in 6-12 Year Old HIV Infected Children: 48-Week Results. Presented at: CROI 2016; 2016 Feb 23.

Citation

Erin McGuire, Youyi Fong, Coleen Cunningham, Elizabeth McFarland, William Borkowsky, Petronella Muresan, Erika Kunz, Julie McElrath, Hau-Xi Liao, Barton Haynes, Georgia Tomaras, Sallie Permar, Genevieve Fouda. HIV exposed infants vaccinated with a rgp120/MF-59 vaccine have higher magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine. Presented at: Keystone HIV Vaccine Meeting.

Citation

Sallie Permar, Erin McGuire, Youyi Fong, Coleen Cunningham, Elizabeth McFarland, William Borkowsky, Petronella Muresan, Erika Kunz, Julie McElrath, Susan Barnett, Hua-XI Liao, Barton Haynes, Georgia Tomaras, Genevieve Fouda. Higher frequency V1V2 IgG3 responses in infants compared to adults immunized with the same rgp120 vaccine. Presented at: CROI 2016.

Citation

Pregnancy and Birth Outcomes of Perinatally HIV-infected Women in the U.S.: A Combined Analysis of the PHACS SMARTT study and IMPAACT P1025 Protocol.

Citation

Michael Boivin, Lillian Wambuzi, Rachel Kawalazira, Limbika Maliwichi-Senganimalunje, Alla Sikorskii, Itziar Familiar-Lopez, Agatha Kuteesa, Mary Nyakato, Alex Mutebe, Mai Nakitende, MacPherson Mallewa, Horacio Ruisefior-Escudero, Jim Aizire, Taha Taha, Mary Glenn Fowler. Neurodevelopmental effects of type of antepartum and postpartum PMTCT ARV exposure on Ugandan and Malawian PROMISE HIV-exposed uninfected children at 12, 24, and 48 months of age. Presented at: IAS 2017.

Citation

Patricia Flynn, Taha Taha, Mae Cababasay, Kevin Butler, Mary Glenn Fowler, Lynne Mofenson, Maxensia Owor, Susan Fiscus, Lynda Stranix-Chibanda, Anna Coutsoudis, Devasena Gnanashanmugam, Nahida Chakhtoura, Katie McCarthy, Cornelius Mukuzunga, Bonus Makanani, Dhayendre Moodley, Teacler Nematadzira, Bangini Kusakara, Sandesh Patil, Tichaona Vhembo, Raziya Bobat, Blandina Mmbaga, Maysseb Masenya, Mandisa Nyati, Gerhard Theron, Helen Mulenga, David Shapiro, PROMISE Study Team. Role of maternal viral load and CD4 count on perinatal HIV-1 transmission during breastfeeding in the PROMISE postpartum component. Presented at: IAS 2018.

Citation

Coleen K. Cunningham, Elizabeth J. McFarland, Edmund V. Capparelli, Petronella Muresan , Leavitt Morrison, Charlotte Perlowski , Megan Valentine , Betsy Smith , John R. Mascola, Barney Graham, IMPAACT P1112 team. Safety & Pharmacokinetics of Multiple Doses of a Potent Anti-HIV Monoclonal Antibody, VRC01, in HIV-Exposed Newborns. Presented at: CROI 2018.

Citation

Margaret McManus, Eric R. Weiss, Eric Mick, Katherine Luzuriaga, PACTG 356 Investigators. Quantitative HIV-1 Antibodies Predict Blood RNA and DNA Levels in Children on cART. Presented at: CROI 2018.